Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: 1. Can combining tebentafusp with IL-2 improve tumor response and overall survival? 2. What are the benefits and side effects of this combination therapy? All participants will receive both

Trial Details

NCT ID
NCT07063875
Phase
PHASE1 / PHASE2
Sponsor
St Vincent's Hospital, Sydney
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Aldesleukin
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic UM or unresectable UM patients
  • HLA-A\*02:01 positive
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • RECIST 1.1 defined progression on single-agent Tebentafusp, with no other intervening systemic therapies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →